Financings

4s3 Bioscience Inc. raised $20 million in Series A funding for orphan neuromuscular disorders.

Amicus Therapeutics Inc. is raising $57 million in a public stock offering.

Amylin Pharmaceuticals Inc. is raising $203 million in a public stock offering.

Aragon Pharmaceuticals Inc. raised $42 million in an oversubscribed Series C financing.

Bellicum Pharmaceuticals Inc. raised $20 million in a Series B financing.

NeuroPhage Pharmaceuticals Inc. secured $9 million in a Series B-1 financing.

Promedior Inc. pulled in $21.5 million in the first closing of a Series D financing.

Shield Therapeutics Ltd. raised $13.9 million from an existing investor.

Sosei Co. Ltd. raised $10.2 million in a private placement of stock.

TG Therapeutics Inc. raised $25 million and reverse-merged with Manhattan Pharmaceuticals Inc.

XOMA Corp. raised about $39.2 million in a public offering of stock and warrants.

Deals

Lipid Therapeutics GmbH licensed its ulcerative colitis drug to Dr. Falk Pharma GmbH.

Medicago Inc. signed a virus-like particle vaccine research deal with Mitsubishi Tanabe Pharma Corp.

Mersana Therapeutics Inc. signed a $270 million antibody-drug conjugate deal with Endo Pharmaceuticals Inc.

. . . And More

Check BioWorld Today for coverage of the American Academy of Allergy Asthma and Immunology meeting and the Conference on Retroviruses and Opportunistic Infections.

AMAG Pharmaceuticals Inc.'s Feraheme (ferumoxytol) showed noninferiority in iron-deficiency anemia.

Astex Pharmaceuticals Inc. and Eisai Inc. got a complete response letter for Dacogen (decitabine) in elderly AML.

Columbia Laboratories Inc. is cutting its work force by 42 percent, from 24 employees to 14 employees.

Discovery Laboratories Inc. got a long-awaited FDA approval of Surfaxin (lucinactant intratracheal suspension).

Johnson & Johnson's Zytiga (abiraterone acetate) got good data in a Phase III earlier-stage prostate cancer study.

Myrexis Inc. is cutting back; it will have 30 employees by March 31, and 10 employees at June 30.

NeurogesX Inc. got a complete response letter for Qutenza's expansion into HIV-associated peripheral neuropathy; the biotech also laid off 57 percent of its work force.